Olympus Biotech International

Biotechnology Division of Olympus, Inc. Olympus has long been involved in R&D and business activities relating to various aspects of regenerative medicine. In December 2010, Olympus Corporation announced the establishment of Olympus Biotech Corporation, and in February 2011, completed its acquisition of Osteogenic Protein-1 (OP-1™) bone-related assets from Stryker Biotech (a division of Stryker Corporation).

Status: 

Out of Business

Industries: 

Employee Count Range: 

51-200

Company type: 

Public Company

Founded year: 

2011

Share this page